Moroctocog alfa (BDDrFVIII)

Specification

• Cat#: THP-0085
• Product Name: Moroctocog alfa (BDDrFVIII)
• Cas No: 284036-24-4
• Description: The product, also known as B domain deleted recombinant factor VIII, is a recombinant DNA-based product with functional characteristics comparable to those of endogenous coagulation Factor VIII, the essential human blood clotting protein that is impaired in Hemophilia A. The product is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function. The product is produced through recombinant DNA technology and purification, resulting in a 1438 amino acid, 170 kDa protein. Clinical evaluation has shown that BDDrFVIII is pharmacokinetically equivalent to full-length recombinant FVIII.
• Sequences: Not Available
• Species: Human
• Molecular Weight: 173000.0 Da (glycosylated)
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Endotoxin: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 250U-3000U/vial
• Application: The product is approved by Health Canada for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia). The product is also approved by the European Medicines Agency for the treatment and prophylaxis of bleeding in patients with Haemophilia A (congenital factor VIII deficiency).

Pharmaceutical Information

• Pharmaceutical Application: Moroctocog alfa
• Targets: Target 1. Coagulation factor X; Target 2. Phytanoyl-CoA dioxygenase, peroxisomal; Target 3. Coagulation factor IX; Target 4. Asialoglycoprotein receptor 2; Target 5. 78 kDa glucose-regulated protein; Target 6. Calreticulin; Target 7. Calnexin; Target 8. Protein ERGIC-53; Target 9. Prolow-density lipoprotein receptor-related protein 1; Target 10. Multiple coagulation factor deficiency protein 2; Target 11. von Willebrand factor; Enzyme 1. Prothrombin; Enzyme 2. Vitamin K-dependent protein C

Reviews (1)

6/12/2024

I am happy to say that the therapeutic protein is working as expected and we are delighted to see much better results with our ELISA setup now.